185.96 USD
-1.02 (-0.55%)
185.96 USD
0 (0%)
Overall AXSM gets a fundamental rating of 2 out of 10. We evaluated AXSM against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AXSM have multiple concerns. While showing a medium growth rate, AXSM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year AXSM has reported negative net income.
- AXSM had a negative operating cash flow in the past year.
- AXSM had negative earnings in each of the past 5 years.
- AXSM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- AXSM has a Return On Assets of -34.31%. This is comparable to the rest of the industry: AXSM outperforms 47.64% of its industry peers.
- Looking at the Return On Equity, with a value of -311.44%, AXSM is doing worse than 75.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.31% | ||
| ROE | -311.44% | ||
| ROIC | N/A |
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of AXSM (91.86%) is better than 93.72% of its industry peers.
- The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, AXSM has more shares outstanding
- The number of shares outstanding for AXSM has been increased compared to 5 years ago.
- AXSM has a worse debt/assets ratio than last year.
2.2 Solvency
- AXSM has an Altman-Z score of 6.97. This indicates that AXSM is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of AXSM (6.97) is better than 78.53% of its industry peers.
- AXSM has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 2.61, AXSM is doing worse than 80.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.61 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.97 |
ROIC/WACCN/A
WACC9.44%
2.3 Liquidity
- A Current Ratio of 1.57 indicates that AXSM should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.57, AXSM is doing worse than 71.20% of the companies in the same industry.
- AXSM has a Quick Ratio of 1.50. This is a normal value and indicates that AXSM is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.50, AXSM is not doing good in the industry: 62.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 28.48% over the past year.
- Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 65.83%.
EPS 1Y (TTM)28.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.85%
Revenue 1Y (TTM)65.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%63.22%
3.2 Future
- The Earnings Per Share is expected to grow by 39.35% on average over the next years. This is a very strong growth
- AXSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.84% yearly.
EPS Next Y37.85%
EPS Next 2Y46.16%
EPS Next 3Y52.16%
EPS Next 5Y39.35%
Revenue Next Year64.25%
Revenue Next 2Y61.46%
Revenue Next 3Y58.65%
Revenue Next 5Y46.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- AXSM is valuated quite expensively with a Price/Forward Earnings ratio of 227.65.
- Based on the Price/Forward Earnings ratio, AXSM is valued a bit cheaper than the industry average as 67.02% of the companies are valued more expensively.
- AXSM is valuated expensively when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 227.65 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- A more expensive valuation may be justified as AXSM's earnings are expected to grow with 52.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.16%
EPS Next 3Y52.16%
5. Dividend
5.1 Amount
- AXSM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AXSOME THERAPEUTICS INC / AXSM FAQ
What is the fundamental rating for AXSM stock?
ChartMill assigns a fundamental rating of 2 / 10 to AXSM.
Can you provide the valuation status for AXSOME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 1 / 10 to AXSOME THERAPEUTICS INC (AXSM). This can be considered as Overvalued.
How profitable is AXSOME THERAPEUTICS INC (AXSM) stock?
AXSOME THERAPEUTICS INC (AXSM) has a profitability rating of 1 / 10.
Can you provide the financial health for AXSM stock?
The financial health rating of AXSOME THERAPEUTICS INC (AXSM) is 2 / 10.
What is the earnings growth outlook for AXSOME THERAPEUTICS INC?
The Earnings per Share (EPS) of AXSOME THERAPEUTICS INC (AXSM) is expected to grow by 37.85% in the next year.